Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma.
D000328:Adult; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D001500:BCG Vaccine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D006968:Hypersensitivity, Delayed; D007093:Imidazoles / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D051379:Mice; D009369:Neoplasms / Q000276:immunology; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D011379:Prognosis; D012878:Skin Neoplasms / Q000188:drug therapy*
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D001500:BCG Vaccine; D007093:Imidazoles; D009607:Nitrosourea Compounds